77 Days
Source:
الوئام
_1777294237270_124456903.png&w=64&q=75){kind=small}
Intisimiran Vaccine for Skin Cancer
The article discusses the development of a new vaccine for treating melanoma skin cancer using messenger RNA (mRNA) technology, named "Entisimiran." This vaccine has shown promising results in reducing the likelihood of disease recurrence and spread. The study involved 1,137 high-risk patients whose tumors were surgically removed; they received treatment for approximately one year, with no new safety concerns emerging. The results demonstrated a 49% reduction in the risk of cancer recurrence after five years, with combination therapy outperforming monotherapy. The companies are preparing for discussions with regulatory authorities, and this treatment is expected to improve outcomes for melanoma patients while reducing costs by avoiding the need for patient-derived cell manufacturing.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)